Search

Displaying results 381 - 390 of 1777 in total
  1. Drug

    Simoctocog alfa

    go.drugbank.com/drugs/DB09108
    Approved

    Simoctocog alfa is a recombinant B-domain deleted (BDD) rFVIII produced in genetically modified human embryonic kidney (HEK) 293F cells. The harvested product is concentrated and purified by a series of chromatography steps. It is an ant...

  2. Drug

    Atogepant

    go.drugbank.com/drugs/DB16098
    ApprovedInvestigational

    It was developed by AbbVie and received FDA approval under the brand name Qulipta in September 2021.

  3. Drug

    Liothyronine

    go.drugbank.com/drugs/DB00279
    ApprovedInvestigationalVet approved

    [T457] The exogenous liothyronine product was developed by King Pharmaceuticals and FDA approved in 1956.[L5578]

  4. Drug

    Rurioctocog alfa pegol

    go.drugbank.com/drugs/DB16007
    ApprovedInvestigational

    Rurioctocog alfa pegol is a pegylated recombinant human coagulation factor VIII or antihemophilic factor. Factor VIII is an essential protein involved in normal blood clotting; thus, a deficient level of functional factor VIII is associa...

  5. Drug

    Bictegravir

    go.drugbank.com/drugs/DB11799
    ApprovedInvestigational

    Bictegravir is a recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and HIV-2 infection. It has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet.

  6. Drug

    Telisotuzumab vedotin

    go.drugbank.com/drugs/DB15104
    ApprovedInvestigational

    [L53193] Telizotuzumab vedotin-tllv was approved by the US FDA in May 2025 for previously treated advanced NSCLC patients with high c-Met protein overexpression,[L53158,L53183] becoming the first treatment

  7. Drug

    Ganaxolone

    go.drugbank.com/drugs/DB05087
    ApprovedInvestigational

    [L41130] It was approved under the brand name ZTALMY by the US FDA in March 2022 for the treatment of seizures associated with CDKL5 deficiency disorder (CDD), becoming the first FDA-approved treatment

  8. Drug

    Prazosin

    go.drugbank.com/drugs/DB00457
    ApprovedInvestigational

    Prazosin is marketed by _Pfizer_ and was initially approved by the FDA in 1988.[L5828] It belongs to the class of drugs known as alpha-1 antagonists.

  9. Drug

    Linagliptin

    go.drugbank.com/drugs/DB08882
    ApprovedInvestigational

    Linagliptin was approved by the FDA on May 2, 2011[L9557].

  10. Drug

    Zolbetuximab

    go.drugbank.com/drugs/DB15118
    ApprovedInvestigational

    [A264723] Zolbetuximab was approved by the FDA in October 2024 for use in patients with HER2 negative, CLDN18.2-positive gastric and GEJ adenocarcinomas.[L51943,L51923]